Huynh, Pacific
Hoffmann, Jan D.
Gerhardt, Teresa
Kiss, Máté G.
Zuraikat, Faris M.
Cohen, Oren https://orcid.org/0009-0004-2827-9063
Wolfram, Christopher https://orcid.org/0009-0002-8113-9102
Yates, Abi G.
Leunig, Alexander https://orcid.org/0000-0002-9179-9203
Heiser, Merlin https://orcid.org/0000-0001-5232-0688
Gaebel, Lena
Gianeselli, Matteo https://orcid.org/0000-0003-3726-3595
Goswami, Sukanya
Khamhoung, Annie
Downey, Jeffrey
Yoon, Seonghun
Chen, Zhihong https://orcid.org/0000-0001-7403-7015
Roudko, Vladimir
Dawson, Travis
Ferreira da Silva, Joana
Ameral, Natalie J.
Morgenroth-Rebin, Jarod
D’Souza, Darwin
Koekkoek, Laura L.
Jacob, Walter https://orcid.org/0000-0001-9649-4989
Munitz, Jazz https://orcid.org/0000-0002-9173-2666
Lee, Donghoon https://orcid.org/0000-0003-0453-6059
Fullard, John F. https://orcid.org/0000-0001-9874-2907
van Leent, Mandy M. T. https://orcid.org/0000-0002-9747-1022
Roussos, Panos https://orcid.org/0000-0002-4640-6239
Kim-Schulze, Seunghee
Shah, Neomi
Kleinstiver, Benjamin P. https://orcid.org/0000-0002-5469-0655
Swirski, Filip K. https://orcid.org/0000-0002-3163-9152
Leistner, David
St-Onge, Marie-Pierre https://orcid.org/0000-0003-1354-1749
McAlpine, Cameron S. https://orcid.org/0000-0002-9832-6345
Article History
Received: 15 November 2023
Accepted: 23 September 2024
First Online: 30 October 2024
Competing interests
: C.S.M. is a consultant for Granite Bio. J.F.d.S. and B.P.K. are inventors on patents or patent applications filed by Mass General Brigham (MGB) that describe genome engineering technologies. B.P.K. is a consultant for EcoR1 capital and Novartis Venture Fund, and is on the scientific advisory board of Acrigen Biosciences, Life Edit Therapeutics and Prime Medicine. B.P.K. has a financial interest in Prime Medicine, a company that is developing therapeutic CRISPR–Cas technologies for gene editing. The interests of B.P.K. were reviewed and are managed by Massachusetts General Hospital (MGH) and MGB in accordance with their conflict-of-interest policies. The other authors declare no competing interests.